Parmodia Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Pemafibrate

Indications/Uses

Adjunctive therapy to diet or exercise to reduce triglycerides & increase HDL-C levels in patients w/ dyslipidemia characterised by high triglyceride ≥150 mg/dL w/ associated risk eg, HTN & smoking.

Click to view Parmodia detailed prescribing information

Dosage/Direction for Use

Adult Usual dose: 0.1 mg bd. Max: 0.2 mg bd. Renal impairment Max: 0.2 mg daily.

Click to view Parmodia detailed prescribing information

Overdosage

View Parmodia overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity. Cholelithiasis. Concomitant use w/ cyclosporine or rifampicin. Severe hepatic disorder, Child-Pugh grade B or C cirrhosis, or biliary obstruction. Pregnancy.

Click to view Parmodia detailed prescribing information

Special Precautions

Discontinue use if diffuse myalgia, myositis, muscle cramps & weakness &/or marked increased creatine kinase (>5 x ULN) is present. History of cholelithiasis; preexisting muscular disease. Periodically monitor liver & renal function. Concomitant use w/ HMG-CoA reductase inhibitors. Hepatic disorder (Child-Pugh grade A cirrhosis). Renal impairment. Avoid use during lactation. Low birth wt infants, newborns, infants & childn. Elderly.

Click to view Parmodia detailed prescribing information

Use In Pregnancy & Lactation

Click to view Parmodia detailed prescribing information

Adverse Reactions

Cholelithiasis; DM; increased blood creatine phosphokinase.

Click to view Parmodia detailed prescribing information

Drug Interactions

Muscle toxicity w/ HMG-CoA reductase inhibitors eg, pravastatin Na, simvastatin, fluvastatin Na. Increased plasma conc w/ clopidogrel sulfate, clarithromycin, HIV PIs (eg, ritonavir), fluconazole. Decreased plasma conc w/ anion exchange resins eg, cholestyramine, colestimide; strong CYP3A inducers eg, carbamazepine, phenobarb, phenytoin, foods containing Hypericum perforatum (St. John's wort).

Click to view Parmodia detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Parmodia detailed prescribing information

Storage

View Parmodia storage conditions for details to ensure optimal shelf-life.

Description

View Parmodia description for details of the chemical structure and excipients (inactive components).

Action

View Parmodia mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Dyslipidaemic Agents

ATC Classification

C10AB12 - pemafibrate ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia.

Regulatory Classification

Presentation/Packing

Form

Parmodia FC tab 0.1 mg

Packing/Price

10 × 10's

Parmodia

Manufacturer:

Kowa

Distributor:

DKSH